title: Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman.
authors.affiliation: aDepartment of Pharmacy bDepartment of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, The Netherlands cDepartment of Pediatric Pneumology and Immunology dDepartment of Obstetrics eDepartment of Neonatology, Charité Universitätsmedizin, Berlin, Germany.
authors.forename: Stein
authors.initials: S
authors.lastname: Schalkwijk
authors.forename: Cornelia
authors.initials: C
authors.lastname: Feiterna-Sperling
authors.forename: Katharina
authors.initials: K
authors.lastname: Weizsäcker
authors.forename: Angela
authors.initials: A
authors.lastname: Colbers
authors.forename: Christoph
authors.initials: C
authors.lastname: Bührer
authors.forename: Rick
authors.initials: R
authors.lastname: Greupink
authors.forename: Frans G M
authors.initials: FG
authors.lastname: Russel
authors.forename: David
authors.initials: D
authors.lastname: Burger
mesh_terms: D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage*; D015497:HIV-1; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D010078:Oxazines; D010879:Piperazines; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011728:Pyridones; D000099226:Dolutegravir
chemical_list: D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir